Be the first person to write a business review for PharmaGap Inc.

PharmaNet, a global, drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. PharmaNet offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. In addition, PharmaNet offers technology tools for managing clinical trial data.

Pharsight wants to shorten the path to market for tomorrow's pharmaceutical breakthroughs. The company's software and consulting services aim to take some of the guesswork out of the drug development process for pharmaceutical and biotech firms, helping them choose the most promising drug candidates, to design effective clinical trials, and to keep up with regulatory reporting. Pharsight's WinNonlin and WinNonMix applications, for instance, analyze research and clinical data to help companies develop appropriate dosing regimens for clinical trials. And its consulting services help them make key strategy decisions about the future of development programs. Pharsight was acquired by Tripos in 2008.

Phase 2 Discovery partners with pharmaceutical companies to develop early-stage drug candidates that could treat various central nervous system diseases and conditions. The company also acquires drug candidates, takes them through Phase I and II clinical studies, and then offers the company the option of re-acquiring them Phase 2's goal is to speed up the discovery process for multiple compounds that could aid patients with psychiatric and neurological disorders.

Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic diseases. The drug development company's lead product candidate dutogliptin is an oral-dose treatment aiming to stabilize glucose levels in patients with Type 2 diabetes. Other pipeline candidates target infectious and autoimmune diseases, including hepatitis C and certain types of cancer. The biotechnology firm's drug candidates focus on inhibiting complex proteins (enzymes) that promote disease within the body. The company is owned by a number of private investors.

Phytopharm is hunting for better drugs. The company struck a deal with Unilever in late 2004 to develop a slimming aid based on the African cactus hoodia, used in Africa to stave off hunger during hunting trips. This developer of botanical pharmaceuticals concentrates on four drug-discovery areas -- obesity and metabolic disease, neurodegeneration, inflammation, and dermatology. In addition, Phytopharm markets two veterinary dermatology products in the UK.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.